PREPARATION AND EVALUATION OF NIOSOMES OF BRIMONIDINE TARTRATE AS OCULAR DRUG DELIVERY SYSTEM by ,HARISH,GANESH,CHARYULU,SATYNARAYANA, P. PRABHU, MARINA KOLAND, K.VIJAYNARAYAN
JPRHC 
Research Article 




PREPARATION AND EVALUATION OF NIOSOMES OF BRIMONIDINE TARTRATE AS OCULAR DRUG 
DELIVERY SYSTEM 
 
P. PRABHU*, MARINA KOLAND,  K. VIJAYNARAYAN,  NM. HARISH, D. GANESH, RN CHARYULU,               
 D. SATYNARAYANA. 
For author affiliations, see end of text 





Nioosomes of brimonidine tartrate were prepared by 
film hydration method. The prepared vesicles were 
evaluated for photomicroscopic characteristics, 
entrapment efficiency, in vitro, ex- in vitro drug 
release, in vivo intra ocular pressure lowering activity. 
Methods employed for the preparation of vesicles 
were found to be simple and reproducible, produced 
vesicles of acceptable shape and size with unimodal 
frequency distribution pattern. The in vitro, ex-in vitro 
drug release studies showed that there was  a slow and 
prolonged release of drug which followed zero order 
kinetics. The intra ocular pressure lowering activity of 
prepared formulations were determined and compared 
with pure drug solution. It was found that intra ocular 
pressure lowering action was sustained for longer 
period of time. Stability study data revealed that the 
formulations were found to be stable when stored at 
refrigerator temperature (2 °C to 8 °C) and at 25 °C 
with no change in shape and drug content. Results of 
the study indicated that it is possible to develop a safe 
and physiological effective topical niosomal 
formulation which is patient compliance. 
KEYWORDS: Niosome, film hydration,  
bromonidine tartrate, intra ocular pressure.
 
INTRODUCTION 
The main objective of drug delivery system to the eye 
is to improve existing ocular dosage forms and exploit 
newer drug delivery system for improving the 
therapeutic efficiency. Topical application of eye 
drops is the most common method of administering 
drugs to the eye in the treatment of ocular diseases. 
Topical and localized applications are still an 
acceptable and preferred route, such dosage forms are 
no longer sufficient to overcome the various ocular 
diseases like glaucoma due to poor bioavailability, due 
to the efficient mechanism protecting the eye from 
harmful materials and agents. This includes reflex, 
blinking, lachrymation, tear turnover, and drainage of 
tear results in the rapid removal of the drug from eye 
surface. Similarly frequent instillation of concentrated 
medication is required at the site of action which is 
patient incompliance1. Vesicular drug delivery 
systems allows the entrapment of drug molecule into 
lipid bilayer or surfactant vesicles and thus increase 
drug concentration at the site of application with 
sustained drug delivery of medicament, which results 
in improved bioavailability. Such vesicles (liposome 
and niosome) acts as carrier for controlled ocular drug 
delivery by preventing metabolism of drug from 
enzymes present at the corneal epithelial surface. 
Vesicle entrapped drug can be easily administered in 
liquid dosage forms such as eye drops with patient 
compliance, modulated drug release profile and high 
drug pay load. Niosomes  can encapsulate both 
lipophilic and hydrophilic drugs and protect against 
acidic and enzymatic effects in vivo. They offer 
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several advantages over liposomes such as higher 
chemical stability, intrinsic skin penetration enhancing 
properties and lower costs. However, there may be 
problems of physical instability of niosomes during 
the storage, which includes vesicles aggregation, 
fusion, leaking or hydrolysis of encapsulated drugs. 
This may affect the shelf life of the niosomes2
,3.  
 
Brimonidine tartrate is α2-adrenergic agonist indicated 
in open angle glaucoma, which is common form of 
glaucoma. Glaucoma is group of diseases of optic 
nerve involving loss of retinal ganglion cells. 
Increased intra ocular pressure (IOP) is significant risk 
factor for the development of glaucoma. At present the 
eye drops (0.2%) of the said drug is available in the 
market all over the world. However, the drug has to be 
instilled into the eye 3-4 times a day4, 5.  To avoid such 
frequent administration of the drug, in the present 
study an attempt was made to develop a niosomal drug 
delivery system of brimonidine tartrate for ocular 
administration and investigated its intraocular pressure 
lowering activity.  
 
MATERIALS AND METHODS 
Materials 
 
Brimonidine tartrate was a gift sample from FDC Ltd,  
Aurangabad, India. Cholesterol,  Span 60 were 
obtained from CDH laboratories Ltd, New Delhi.  
Diethyl ether, chloroform, methanol, potassium 
dihydrogen phosphate, disodium hydrogen phosphate 
were obtained from E-Merck India Ltd, Mumbai. 
Methods 
Preparation of niosomes: 
In the present study three niosomal 
formulations of brimonidine tartrate were prepared by 
film hydration method6 as described by Bangham et.al. 
(1965). All the lipid components including surfactant, 
span 60, as per the formula were taken in round 
bottom flask and dissolved into sufficient quantity (10 
ml) of organic solvent (chloroform). Organic solvent 
was evaporated under reduced pressure, at a 
temperature about 60 °C, till the lipid film was 
formed. Dried lipid film obtained was hydrated with 
aqueous phase of phosphate buffer pH 7.4 (10 ml) 
containing drug. The flask was shaken for 1 h to get 
niosomal formulation. Niosomal formulations 
prepared were coded as NF1, NF2 and NF3. Once a 
stable suspension was produced, subjected to ultra 
probe sonication by transferring the colloidal 
suspension on to a glass vial. The probe tip of the ultra 
sonicator was just dipped into the suspension (care 
should be taken such that the probe tip does not touch 
the bottom of the glass vial during sonication). 
Sonication was done in 2 cycles. First the niosomal 
suspension was sonicated at 80% amplitude with a 
pulse of 0.5 cycles per second for a period of  3 min, 
followed by 3 min rest (excess heat may be generated 
during probe sonication, which may damage the 
lipids). After 3 min, second cycle was processed for 3 
min at 80% amplitude with 0.5 sec pulse for another 3 
min. 
Photomicroscopic study of niosomes: 
The niosomal suspensions was subjected to 
size analysis under a microscope (10×400 
magnification) fitted with a calibrated ocular 




JPRHC                                       Volume 2                                Issue 4 293-301 
 
Drug entrapment efficiency determination: 
Entrapment efficiency of brimonidine tartrate in 
the niosomes was determined as follows: After sonication, 
1 ml of niosomal suspension (SUVs) was taken in a 1 ml 
micro-centrifuge tube. Centrifuged at 20,000 rpm for 1 h, at 
4 ºC in a cold centrifuge to get a white pellet. This was 
settled at the bottom of the centrifuge tube. Supernatant 
was separated as it contains unentrapped drug which is 
highly soluble in PBS 7.4, using a micro-pipette. To the 
remaining pellet in the centrifuge tube 500 µl of 0.1 N 
NaOH (as drug is highly soluble in 0.1N NaOH) was added 
and vertexed thoroughly for 3 min. After vertexing a white 
suspension was obtained and 1 ml of this suspension was 
taken in a micro-pipette and transferred to a test tube. To 
this 5 ml methanol was added which resulted in a clear 
solution, this was further vertexed in a vertex mixer for 2 
min such that to ensure that the niosomes are lysed 
completely to release the drug7. This solution (1 ml) was 
further diluted with methanol and the absorbance was 
determined using a UV spectrophotometer (Jasco V-530).  
The entrapment efficiency (EE) was calculated using the 
following formula:  
                                                      Entrapped drug (mg)                                                             
Percentage entrapment (%EE)    =       ----------------------------    × 100 
                                                Total drug added (mg) 
 
In vitro drug release study: 
In vitro drug release study of niosomal 
formulations was studied by membrane diffusion 
technique7. In vitro diffusion cell was made using 
cellophane membrane as a semipermeable membrane. The 
diffusion cell consists of a beaker, magnetic stirrer with 
temperature control and test tube with both ends open. One 
end of test tube was closed using treated cellophane 
membrane as semi permeable membrane and other end was 
open to introduce the niosomal formulation. The diffusion 
medium  was freshly prepared phosphate buffer pH 7.48 
solution (100 ml) equilibrated at 37± 0.5°C temperature. 
The niosomal formulation (5 ml) was placed inside the 
diffusion cell through open end of test tube on the 
cellophane membrane. The diffusion medium of freshly 
prepared phosphate buffer pH 7.4 solution (100 ml) was 
placed inside the beaker such way that the lower surface of 
cellophane membrane makes contact with the buffer. The 
temperature of buffer solution was maintained at 37± 0.5 
°C and stirred with magnetic stirrer throughout the study 
period. Aliquots (5 ml) of the medium was withdrawn 
every hour and replaced with fresh diffusion medium of 
phosphate buffer pH 7.4, to maintain constant volume (sink 
condition). The samples were analyzed 
spectrophotometrically for concentration of brimonidine 
tartrate at 320 nm.  
Ex- in vitro drug release study 
Ex- in vitro drug release study of prepared niosomes was 
studied by membrane diffusion technique. In this study in 
vitro diffusion cell was made using porcine cornea as 
semipermeable membrane. All the procedures followed 
were similar to that explained under in vitro drug release 
study, except the cellophane membrane was replaced by 
fresh porcine cornea7. 
In vivo intra ocular pressure lowering activity: 
In vivo intra ocular pressure lowering activity of 
selected niosomal preparation (NF3) of   brimonidine 
tartrate was studied in normotensive male albino rabbits 
weighing 1.2 to 2.5 Kg. This study was conducted in 
accordance with CPCSEA (guidelines and the experimental 
protocol was approved by Institutional Animal Ethics 
Committee (K.S. Hegde Medical Academy).  The animals 
were housed under well controlled conditions of 
temperature (22± 2 °C), humidity (55±5%) and 12/12 – h, 
light-dark cycle, were given access to food and water. The 
rabbits were divided into three groups, each containing of 
single male albino rabbit. The protocol of the experiment 
was approved by the Institutional Animal Ethics 
Committee.  To induce acute glaucoma, 5% dextrose 
solution (15 ml/kg) was intravenously infused through 
marginal ear vein. The basal intraocular pressure was 
measured by tonometere. The drug formulations (20 µl, 
drug equivalent to pure drug solution 0.2%) were 
administered to rabbits in different sequence. In sequence 
JPRHC 
Research Article 
JPRHC                                       Volume 2                                Issue 4 293-301 
 
1: Drug formulations were administered 30 min before the 
administration of dextrose solution. In sequence 2: Drug 
formulations and dextrose solution were administered 
together. In sequence 3: Drug formulations were 
administered 30 min after the administration of dextrose 
solution. The intraocular pressure (IOP) changes were 
recorded every 30 min till the pressure difference between 
the control eye and treated eye is zero. Formulation was 
instilled on to corneal surface of one eye and contra lateral 
eye was remaining as control.  Intraocular pressure (IOP) 
was measured by tonometry method with the help of 
Schniotz tonometere and mean was taken at three times 
fixed interval.  All IOP measurements were carried out by 
the same operator, using same tonometere. Each rabbit was 
given washout period of three days after every treatment. 
The ocular hypotensive activity was expressed as the 
average difference in IOP between the treated and control 
eye of the same rabbit, according to the equation    ∆ IOP = 
IOP of Treated Eye – IOP of control Eye8, 9. 
Stability study: 
For stability testing, the sonicated niosomal suspension of  
was stored away from light in sealed 2 ml micro centrifuge 
eppendroff tubes in refrigerator (4-8 ºC) and at room 
temperature (25 ºC) for 3 months. Sampling was done by 
withdrawing 100 µl of the supernatant using a micro-
pipette at different time intervals of  2nd day, 4th day, 10th 
day, 20th day, 40th day, 45th day, 60th day, 80th day and 90th 
day respectively. Suitable dilutions were made with PBS 
7.4 whenever sample was withdrawn and UV absorbance 
was determined. The entrapment efficiency was calculated. 
from the regression equation In the present work, stability 
study was carried out for selected formulation NF3, at room 
temperature and  refrigerator (2 °C to 8 °C),  for 3 months 
and evaluated for the drug content10. 
Determination of drug release kinetics: 
To know the mechanism of drug release from 
these formulations, the data were treated according to first-
order (log cumulative percentage of drug remaining vs. 
time), Higuchi’s (cumulative percentage of drug released 
vs. square root of time), and zero order (cumulative amount 
of drug released vs. time) pattern11 
 
RESULTS AND DISCUSSION 
Niosomes were prepared by thin film hydration 
method as per the method described by Bangham et al., 
1965. The molar ratios of surfactant and cholesterol were 
dissolved in 2 ml of a mixture of choloroform: methanol 
(2:1) in a 250 ml round bottom flask. The powder particles 
of lipid mixture don’t seem to dissolve readily in the 
chloroform: methanol solution. So the flask was rotated for 
15 min over the water bath (at a temperature above the 
transition temperature of the lipids) before starting the 
vacuum pump. A very low nitrogen flux (through a 
nitrogen cylinder connected to the evaporator by an inlet 
rubber pipe) was set up during the preparation of niosomes 
to prevent too much oxygen to get dissolved. Gradually the 
nitrogen pressure was raised at the cylinder head until there 
was no pressure difference between the inside and outside 
of flask. The pressure release valve between the cylinder 
and the evaporator prevents the build up of pressure inside 
the apparatus. If this flux is too high the solvent may 
evaporate. Some of the solvent evaporates inevitably during 
this period, but the solution thermalizes and the lipids get 
dissolved. These formulations were characterized in Table 
1. The size of niosomal formulations ranged from 8.00 µ to 
9.37 µ and showed unimodal normal symmetrical 
frequency distribution patterns. All the vesicles were found 
to be spherical in shape (Fig 1). Further, the sonication, 
resulted in much smaller vesicles, which is very essential in 
avoiding the irritation to the eye. The size of particles in 
ophthalmic dosage forms apart from influencing 
bioavailability, plays important role in the irritation 
potential of formulation, hence it is recommended that 
particles of ophthalmic solution should be less than 10 µ to 
minimize irritation to the eye12. Further, the size of  
sonicated  niosomes was found to be 245 nm (Fig. 2). The 
results shows that the amount of drug entrapped in 
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Formulation Ratio (drug: 
cholesterol: span 60) 
Average particle 




NF 1 1:1:1 8.03 32.33 
NF 2 1:1:2 8.27 39.20 
NF 3 1:1:3 9.37 43.40 
 
 




Pure Drug Solution 
Formulation NF 
NF1 NF2 NF3 
1 68.00 ± 1.44 10.69 ± 0.99 14.13 ± 0.99 4.46 ± 0.99 
2 77.40 ± 1.28 19.29 ± 0.98 22.35 ± 1.09 12.86 ± 0.98 
3 78.80 ± 1.32 20.28 ± 0.97 24.91 ± 1.16 14.40 ± 0.99 
4 78.30 ± 1.28 21.42 ± 0.94 26.52 ± 0.98 14.58 ± 0.98 
5      80.00 ± 1.32 22.69 ± 0.99 27.99 ± 0.98 16.67 ± 0.97 
6 79.64 ± 1.46 23.19 ± 0.98 29.30 ± 0.99 16.83 ± 0.98 
7 81.54 ± 1.67 24.19 ± 0.99 31.11 ± 0.97 16.98 ± 1.08 
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Table 3: Comparative Ex-In vitro dissolution profile of different formulations 
 
     Time 
(h) 
Formulation 







1 68.00±1.43 12.89±0.99 07.89±0.99 06.37±0.99 
2 77.41±1.29 15.68±0.98 13.04±0.98 13.12±0.98 
3 78.80±1.31 18.92±0.97 13.36±0.99 14.31±1.09 
4 78.30±1.28 24.76±0.94 14.00±0.98 15.87±1.17 
5 80.00±1.33 27.56±0.99 15.64±0.97 16.59±0.99 
6 79.64±1.45 27.89±0.98 17.56±0.99 18.57±0.98 
7 81.54±1.69 28.56±0.99 17.76±1.05 20.55±0.99 





Fig 1: Photomicrograph of niosomes 
 
 





 Fig. 2.  Change in IOP.  Sequence-1. Drug 
formulations was administered 30 min          
 before  the administration of dextrose solution. 
 
 



































































The comparative in vitro drug release profile summarized 
in Table-3, for pure drug solution and for each formulation. 
It was observed that pure drug solution released 
approximately 78% of drug within 2 h, while niomal 
formulations NF1, NF2 and NF3 showed 18.92 %, 22.50 % 
and 29% drug release respectively in 8 h. The result of in 
vitro drug release profile of formulations showed that 
niosomal formulations provides the prolonged release of 
drug when compared to pure drug solution. Similarly, the 
comparative ex - in vitro drug release profile was 
summarized in Table 3, for pure drug solution and for each 
formulation. It was observed that pure drug solution 
released major amount of drug within 1 h, while the 
niosomal formulations NF3 and NF2 showed 18.89 % and 
22.56 % drug release respectively in 8 h.  Hence, from 
comparative in vitro and ex-in vitro drug release data of 
brimonidine tartrate from liposomes and pure drug solution, 
it has been observed that the amount of drug release 
remained similar. Further the delayed drug release rate may 
be attributed largely to the drug transport by diffusion 
controlled mechanism resulting in prolonged drug release 
profile. The in vitro and ex- in vitro drug release studies 
showed that, there was slow and prolonged release of drug 
from all the formulations and followed zero order kinetics. 
This indicated that the drug release was independent of 
concentration of drug entrapped.  
To study the in vivo performance of prepared formulations, 
intraocular pressure lowering activity was determined. It 
was found that in sequence 1, where drug formulations 
were administered 30 min before the administration of 
dextrose solution (Fig 2), intraocular pressure lowering 
activity with liposomal formulation was sustained for 
longer period (3-4 h). However marketed product though 
showed activity within 30 min, but could not sustain for 
more than 60 min. It was found that the IOP difference 
produced between pure drug solution and niosomes is very 
significant. Niosomal formulations sustained the action for 
prolonged period (Fig 2) of time (240 min). Hence, the 
difference in IOP lowering activity with pure drug solution 
did not last long and sustainability of action was also not 
observed. In sequence 2, formulation and dextrose solution 
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was observed compared to pure drug solution. Further, 
extent of IOP lowering activity was found to be better in 
comparison to marketed product. Whereas for marketed 
product, the effect was observed immediately. The duration 
of intraocular pressure lowering activity remained more or 
less similar to that of sequence 1.  In sequence 3, dextrose 
solution was administered before the administration of 
niosomal formulation and marketed product (Fig 4) and 
intraocular pressure lowering activity with niosomal 
formulation was not found to be significant. However, 
better duration of action was visible to some extent with 
niosomes. It was also observed that at the end of 240 min, 
the effect of all the formulations was found to be nil. This 
may be due to the fact that the induced IOP by injecting 5% 
dextrose solution did not last long. Nevertheless, the 
experimental data justified the sustained action of 
liposomal formulation in comparison to marketed eye 
drops. This may be the reason why in sequence 3, the effect 
of niosomal formulation was not observed to the greater 
extent as in the case of sequence 1 and sequence 2. The 
drug formulations were administered 30 minute after the 
induction of glaucoma.   
However, the better reduction in IOP with niosomes may   
probably due to the better partitioning of drug between 
vesicle and eye corneal surface. Further, it is believed that 
the release of drug from niosome will increase the local 
concentration at corneal surface, after the release from 
vesicle depending on passive diffusion of drug molecule 
across the corneal barrier. The longer contacts time of 
vesicles at corneal surface, leads to higher bioavailability of 
drug. Thus the niosome acts as drug carrier, which changes 
rate and extent of absorption resulting in reduction of IOP 
for prolonged period of time.  
Result of stability study was found to be satisfactory and 
acceptable. The niosomes stored at refrigerator (2 °C to 8 
°C), and room temperature, found to be sufficiently stable 
with no change in shape and no significant difference in 
drug content.  
CONCLUSION: 
Niosomes of brimonidine tartrate allowed a 
significant vesicular carrier system for therapeutic 
effectiveness in terms of duration of action and decrease in 
dose frequency. The in vitro and ex- in vitro drug release 
studies showed that, there was slow and prolonged release 
of drug from all the formulation and followed zero order 
kinetics. The in vivo intraocular pressure lowering activity 
of niosome formulation was found to be significant and 
sustained for long period of time which encourages its 
physiological effectiveness. Thus niosomes offer a 
promising avenue to fulfill the need for an ophthalmic drug 
delivery system that not only has the convenience of a 
drop, but that can localize and maintain drug activity at its 
site of action for a longer period of time thus allowing for a 
sustained action; minimizing frequency of drug 
administration with patient compliance. 
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